ABSIHealthcare · BiotechnologyThe 12 Wall Street analysts covering Absci Corp. hold a median 12-month price target of $15 — +42.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 4 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Absci Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Volatility (16): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ABSI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +42.9% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Oct 2026 | Jefferies | Initiates | Buy | $14 |
| 16 Oct 2026 | Keybanc | Maintains | Overweight | $16 → $20 |
| 16 Oct 2026 | Keybanc | Maintains | Overweight | — |
| 12 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $16 |
| 12 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Oct 2026 | JP Morgan | Maintains | Overweight | $14 → $15 |
| 12 Oct 2026 | JP Morgan | Maintains | Overweight | — |
| 23 Sept 2026 | Needham | Reiterates | Buy | — |
| 23 Sept 2026 | Needham | Reiterates | Buy | $11 |
| 9 Sept 2026 | LifeSci Capital | Initiates | Outperform | — |
| 8 Sept 2026 | BTIG | Maintains | Buy | $13 → $16 |
| 8 Sept 2026 | BTIG | Maintains | Buy | — |
| 12 Aug 2026 | BTIG | Reiterates | Buy | $13 |
| 12 Aug 2026 | BTIG | Reiterates | Buy | — |
| 12 Aug 2026 | Needham | Reiterates | Buy | $11 |
| 12 Aug 2026 | Needham | Reiterates | Buy | — |
| 2 July 2026 | Truist Securities | Maintains | Buy | — |
| 2 July 2026 | Truist Securities | Maintains | Buy | $11 → $17 |
| 25 June 2026 | HC Wainwright & Co. | Maintains | Buy | $8.00 → $16 |
| 25 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ABSI appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Absci Corp. returned +166.5% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 95% of US stocks
Cheaper than 1% of US stocks
Cheaper than 13% of US stocks
Cheaper than 87% of US stocks
Higher than 6% of US stocks
Higher than 12% of US stocks
Higher than 2% of US stocks
Higher than 30% of US stocks
Higher than 20% of US stocks
Higher than 12% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Absci Corp. has a market value of $1.7B and an enterprise value of $1.5B.
Revenue in the twelve months to 30 June 2026: $1.6M. The latest quarter shrank 46.4% year on year.
Net income over the same four quarters: −$121.1M, a −7756.4% net margin.
Diluted earnings per share, trailing twelve months: $−0.80.
Free cash flow in the twelve months to 30 June 2026: −$109.0M.
Trailing P/E: −11.9×; forward P/E: −14.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Absci Corp. employs 140 people — $11K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Absci Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Absci announced it will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, with a fireside chat scheduled for November 10 at 1:00 p.m.
Why it matters — The announcement provides ABSI watchers with details of an upcoming company appearance at an investor conference.
Absci announced that it will report business updates and third-quarter 2026 financial and operating results before market open on November 12, 2026.
Why it matters — ABSI watchers can note the scheduled date for the company’s next quarterly results and business update.
Absci announced preliminary details for its Phase 2 STORYLINE trial of ABS-201, its AI-designed antibody for endometriosis. The trial will assess efficacy and safety in patients with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain, with initiation anticipated in mid-2027.
Why it matters — This provides an early outlook on the clinical advancement of ABSI's lead AI-designed antibody candidate, indicating progress toward a large-market indication.
Absci Corporation presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha. The item reports on the company's participation and availability of the presentation transcript.
Why it matters — A transcript of Absci's presentation at a major healthcare conference gives ABSI watchers insight into the company's updates and positioning as shared with the investment community.
Absci Corporation was upgraded to "Buy" following positive interim Phase 1 data for ABS-201 in androgenetic alopecia (AGA). The therapy demonstrated an excellent pharmacokinetic profile enabling infrequent dosing (2-3 injections per 6 months) and strong safety/tolerability in single ascending dose cohorts. Upcoming catalysts include 13-week interim proof-of-concept data in the second half of 2026 and 26-week topline results in early 2027 for ABS-201 in AGA.
Why it matters — Absi watchers would care because the publication's upgrade reflects encouraging early clinical data for ABS-201 and points to several near-term readouts that could shape the company's outlook for its androgenetic alopecia program.
The 12 Wall Street analysts covering Absci Corp. have a median 12-month price target of $15, with estimates ranging from $10 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Absci Corp., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Absci Corp. 37 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Absci Corp. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +42.9% from the last close, and Ticker Nerd's factor model ranks Absci Corp. 37 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Absci Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABSI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $20 over the next 12 months.
Absci Corp. returned +166.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Absci Corporation is a clinical-stage biopharmaceutical company focused on discovering and designing protein-based therapeutics using generative artificial intelligence and synthetic biology. Absci integrates AI-driven modeling with high-throughput wet lab capabilities to create antibody and other biologic candidates for complex disease areas.
The most recent item we track (GlobeNewsWire, 27 Oct 2026): "Absci to Participate in Upcoming Investor Conferences". Absci announced it will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, with a fireside chat scheduled for November 10 at 1:00 p.m.
Absci Corporation is a clinical-stage biopharmaceutical company focused on discovering and designing protein-based therapeutics using generative artificial intelligence and synthetic biology. Absci integrates AI-driven modeling with high-throughput wet lab capabilities to create antibody and other biologic candidates for complex disease areas. Its current pipeline spans programs in immunology, oncology, inflammatory disease, and dermatology, reflecting a platform approach to drug creation rather than a single-product model. The company also collaborates with pharmaceutical and biotechnology partners to support therapeutic discovery and development efforts. Headquartered in Vancouver, Washington, Absci plays a role in the growing market for AI-enabled drug discovery, where data science and biological engineering are combined to improve how new medicines are identified and optimized.
CEO Mr. Sean McClain · 140 employees · United States · https://www.absci.com
